Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
Tiziana Life Sciences (NASDAQ:TLSA), a biotechnology company focused on immunomodulation therapies, announced that CEO Ivor Elrifi has purchased 193,848 shares of company common stock at $1.65 per share in the open market. The company's lead development candidate is intranasal foralumab, a fully human anti-CD3 monoclonal antibody.
Tiziana Life Sciences (NASDAQ:TLSA), una biotech specializzata in terapie immunomodulanti, ha comunicato che il CEO Ivor Elrifi ha acquistato 193.848 azioni ordinarie della società sul mercato aperto a $1,65 per azione. Il candidato principale in sviluppo è il foralumab intranasale, un anticorpo monoclonale anti-CD3 completamente umano.
Tiziana Life Sciences (NASDAQ:TLSA), una compañía biotecnológica centrada en terapias inmunomoduladoras, anunció que el CEO Ivor Elrifi compró 193.848 acciones ordinarias de la empresa en el mercado abierto a $1,65 por acción. El principal candidato en desarrollo es foralumab intranasal, un anticuerpo monoclonal anti-CD3 totalmente humano.
Tiziana Life Sciences (NASDAQ:TLSA), 면역조절 치료제를 개발하는 바이오텍이 자사 CEO인 Ivor Elrifi가 193,848주의 보통주를 공개시장으로부터 주당 $1.65에 매입했다고 발표했습니다. 회사의 주요 개발 후보물질은 완전 인간 유래의 항-CD3 단클론항체인 비강 투여용 포랄루맙입니다.
Tiziana Life Sciences (NASDAQ:TLSA), une société de biotechnologie axée sur les thérapies immunomodulatrices, a annoncé que le PDG Ivor Elrifi a acheté 193 848 actions ordinaires de la société sur le marché ouvert au prix de 1,65 $ par action. Le candidat principal en développement est le foralumab intranasal, un anticorps monoclonal anti-CD3 entièrement humain.
Tiziana Life Sciences (NASDAQ:TLSA), ein Biotechnologieunternehmen mit Schwerpunkt auf Immunmodulations-Therapien, gab bekannt, dass der CEO Ivor Elrifi 193.848 Aktien des Unternehmens im freien Markt zum Preis von $1,65 pro Aktie erworben hat. Der führende Entwicklungskandidat ist intranasales Foralumab, ein voll menschlicher anti-CD3 monoklonaler Antikörper.
- CEO purchased 193,848 shares worth approximately $320,000, demonstrating confidence in company's future
- Insider buying signals management's positive outlook on company's prospects
- None.
BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its Chief Executive Officer, Ivor Elrifi, has purchased 193,848 shares of Tiziana common stock at a price of
About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).
Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. The non-active SPMS intranasal foralumab Phase 2 trial (NCT06292923) began screening patients in November of 2023. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2]
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
[1] https://www.pnas.org/doi/10.1073/pnas.2220272120
[2] https://www.pnas.org/doi/10.1073/pnas.2309221120
FAQ
How many shares of TLSA stock did CEO Ivor Elrifi purchase in September 2025?
What is the total value of TLSA shares purchased by the CEO in September 2025?
What is Tiziana Life Sciences' main product candidate?
Why is the CEO's purchase of TLSA shares significant?
